OKYO Pharma CEO to Present on Urcosimod at Bio International Convention

Ticker: OKYO · Form: 6-K · Filed: Jun 11, 2025 · CIK: 1849296

Okyo Pharma LTD 6-K Filing Summary
FieldDetail
CompanyOkyo Pharma LTD (OKYO)
Form Type6-K
Filed DateJun 11, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: presentation, biotech, clinical-development

TL;DR

OKYO Pharma CEO Gary Jacob presenting lead drug urcosimod at Bio International Convention on June 11, 2025.

AI Summary

On June 11, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, Ph.D., will present on the development of urcosimod at the Bio International Convention in Boston, MA. The presentation will focus on OKYO's lead clinical candidate.

Why It Matters

This presentation provides an opportunity for OKYO Pharma to showcase its lead drug candidate, urcosimod, to a key industry audience, potentially attracting investment and partnerships.

Risk Assessment

Risk Level: low — The filing is an announcement of a presentation and does not contain new financial information or significant operational changes.

Key Players & Entities

FAQ

What is the specific topic of Dr. Jacob's presentation?

Dr. Jacob's presentation will cover the development of urcosimod, OKYO's lead clinical candidate.

When will the presentation take place?

The presentation will take place during the Bio International Convention in Boston, MA, on June 11, 2025.

Who is presenting on behalf of OKYO Pharma Ltd?

The CEO of OKYO Pharma Ltd, Gary S. Jacob, Ph.D., will be giving the oral presentation.

What is the name of OKYO Pharma's lead clinical candidate?

OKYO Pharma's lead clinical candidate is named urcosimod.

Where is the Bio International Convention being held?

The Bio International Convention is being held in Boston, MA.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on June 11, 2025 by Gary S. Jacob, Ph.D. regarding OKYO Pharma Ltd (OKYO).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing